Abstract
Abstract
Background
Fetal growth restriction (FGR) is one of the main syndromes causing fetal morbidity and mortality. It was known to be associated with different factors including maternal, fetal, and environmental. However, the effect of genetic factors in FGR is not totally understood. Recently, researchers have focused on investigating genetic variants as possible markers of FGR. This especially concerns maternal genetic polymorphisms since they could serve as prenatal prognostic biomarkers. Accordingly, we aimed to study the association of several polymorphisms affecting vital processes of pregnancy with FGR in pregnant women. Targeted polymorphisms include methylenetetrahydrofolate reductase (MTHFR) 677C > T; methionine synthase reductase (MTRR) 66A > G; methionine synthase (MTR) 2756A > G; angiotensinogen (AGT) 704 T > C; and vascular endothelial growth factor A (VEGFA) 634C > G. In addition, this study examined SNP–SNP interactions, linkage disequilibrium (LD), and haplotypes association for these polymorphisms in the studied population.
Results
According to our data, MTRR 66(GG) carriers had increased FGR risk (OR = 3.18, 95% CI 1.31–7.72) while (AG) genotype was associated with lower FGR risk (OR = 0.37, 95% CI 0.17–0.84). AGT 704T > C also showed significant association with FGR with allele (T) as a risk factor. SNP–SNP interactions analysis revealed antagonistic relationship between these two polymorphisms and haplotypes association confirmed this finding. High LD possibility was shown between MTHFR 677C > T and MTR 2756A > G (D′ = 0.999) located on chromosome 1.
Conclusion
We suggest MTRR 66A > G and AGT 704T > C as associated with FGR susceptibility with antagonistic interaction. Result will help to expand our understanding of FGR as a multifactorial syndrome and improve prenatal prognosis using maternal genetic biomarkers, but further studies in different populations are needed to confirm findings.
Funder
This study was funded by the Ministry of Science and Higher Education of the Russian Federation
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Ashour E, Gouda W, Mageed L, Okasha A, Afify M, Fawzi OM (2022) Association of gene polymorphisms of ACE, AGT, and ARNT-like protein 1 with susceptibility to gestational diabetes. Egypt J Med Hum Genet 23(1):59. https://doi.org/10.1186/s43042-022-00273-1
2. Chaudhry SH, Taljaard M, MacFarlane AJ, Gaudet LM, Smith GN, Rodger M, Rennicks White R, Walker MC, Wen SW (2019) The role of maternal homocysteine concentration in placenta-mediated complications: findings from the Ottawa and Kingston birth cohort. BMC Pregnancy Childbirth 19(1):1–10. https://doi.org/10.1186/s12884-019-2219-5
3. Chew LC, Verma RP. Fetal Growth Restriction. [Updated 2022 Jun 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562268/
4. Dall’Asta A, Stampalija T, Mecacci F, Minopoli M, Schera GB, Cagninelli G, Ottaviani C, Fantasia I, Barbieri M, Lisi F, Simeone S (2022) Ultrasound prediction of adverse perinatal outcome at diagnosis of late-onset fetal growth restriction. Ultrasound Obstet Gynecol 59(3):342–349. https://doi.org/10.1002/uog.23714
5. Delforce SJ, Lumbers ER, Ellery SJ, Murthi P, Pringle KG (2019) Dysregulation of the placental renin–angiotensin system in human fetal growth restriction. Reproduction 158(3):237–245. https://doi.org/10.1530/REP-18-0633